This study looks at the use of a special eye implant called OTX-TKI to treat Neovascular Age-Related Macular Degeneration (nAMD), which is a serious eye problem that can make it hard to see. The implant releases a medicine called axitinib directly into the eye. The study wants to see if this treatment is both effective and safe. People who join the study need to be 50 years or older and not have had treatment for nAMD before, which means they are treatment naïve. They must also have a certain level of vision measured by the Best Corrected Visual Acuity (BCVA) test.

• The study is for people aged 50 or older.
• Participants must have good vision in at least one eye.
• People with other serious eye conditions cannot join.